Altus Biologies, Inc

Altus has developed proprietary technology platform, known as Crystalomics , to enable the rapid commercialization of high-value protein-based products. The primary focus is on the 300 billion pharmaceutical industry, where the technology is designed to significantly accelerate the development of both large and small molecule pharmaceuticals. The Crystalomics platform addresses the major limitations in protein-based developments by enabling protein candidates transformation into their crystalline state. The application of the Crystalomics platform is in the development of protein-based biocatalytic products and processes, for use in the production of small molecule pharmaceuticals, for therapeutical purposes. 

---

Crosslinking of enzyme crystals with e.g. glutaraldehyde results in the so-called CLECs produced by Altus Biologies inc. 

Throughout the bulk of this chapter, CLC will be used as an abbreviation for cross-linked enzyme crystal. Occasionally, the abbreviation CLEC will also be used to indicate cross-linked enzyme crystal. This acronym is a registered trademark of Altus Biologies, Inc. (Cambridge, MA) and will be used in discussing work done with various cross-linked enzyme crystals which are commercially available from Altus (Table 1). Finally, the notation CPC will be used to denote cross-linked protein crystal. 

ChiroCLEC -EC is cross-linked crystals of penicillin-G acylase and is available from Altus Biologies, Inc., Cambridge, MA. 

Altus Altus Biologies Inc. 625 Putnam Avenue Cambridge, MA 02139-4807 USA Tel. +1 (617) 299-2900 Fax +1 (617) 299-2999 Email info altus.com http / / www.altus.com Manufacturer of stabilized enzymes for use in industrial, biocatalytical, diagnostic, and medicinal applications. No enzyme production itself. Biocatalytical process development. 

Altus Biologies, Inc., The Presidential Green Chemistry Challenge Awards program, summary of 1997 award entries and recipients, EPA 744-S-97-001, U.S. Environmental Protection Agency, Office of Pollution Prevention and Toxics, Washington, DC, p. 13, 1997. 

Currently, Candida rugosa and Pseudomonas cepacia lipases, thermolysin, subtilisin, and penicillin acylase are commercially available from Altus Biologies Inc. and have proved to be very effective catalysts for the synthesis of peptides and esters, and the resolution of acids, alcohols, amines, and amino acids in a variety of media [370-372,374-377,379-381]. In addition, proteinase K, lactate dehydrogenase, horse liver alcohol dehydrogenase, and rabbit muscle aldolase have also been crossUnked and shown to operate efficiently in synthetic reactions [305,374,378,382,383]. The unique features, and the advantages and drawbacks of using CLECs, are outlined in Table 9. 

Altus Biologies. Cistron Biotechnology, Inc. Matrix Pharmaceutical. Scios... 

---